Patent intelligence · AU
AU 2003222814
PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR AND GLUCOMANNAN
PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR AND GLUCOMANNAN
Patent details — AU 2003222814
- Jurisdiction
- AU
- Status
- expired
- Grant date
- Nov 10, 2003
- Expiration
- Nov 5, 2023
- Applicant
- HOFFMANN LA ROCHE [DE]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 48 A I, A61K 31/ 365 A I, A61K 31/ 736 A I
Quick answer
AU 2003222814 (PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR AND GLUCOMANNAN) is held by HOFFMANN LA ROCHE [DE]. Status: expired. Granted Nov 10, 2003. Expires Nov 5, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- HOFFMANN LA ROCHE [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 48 A I, A61K 31/ 365 A I, A61K 31/ 736 A I, A61K 36/ 00 A I, A61K 36/ 18 A I
More from HOFFMANN LA ROCHE [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2007332640
Powder formulation for valganciclovir
granted -
AU 2001289696
New use of lipase inhibitors
granted -
AU 2001289699
New pharmaceutical composition
expired -
AU 2002212120
Lipase inhibitors for the treatment of dyspepsia
expired -
AU 2001281846
Method for preparing a composition
expired -
AU 2002319189
Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof
expired -
AU 2002257817
Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
expired
Frequently asked questions
What is US patent 2003222814?
AU 2003222814 (PHARMACEUTICAL COMPOSITION COMPRISING A LIPASE INHIBITOR AND GLUCOMANNAN) is held by HOFFMANN LA ROCHE [DE]. Status: expired. Granted Nov 10, 2003. Expires Nov 5, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2003222814?
HOFFMANN LA ROCHE [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does AU 2003222814 expire?
Our index shows an expiration date of Nov 5, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.